The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 09, 2019

Filed:

Jun. 19, 2008
Applicants:

Ravinder Abrol, Pasadena, CA (US);

William A. Goddard, Pasadena, CA (US);

Adam R. Griffith, Pasadena, CA (US);

Victor Wai Tak Kam, New York, NY (US);

Inventors:

Ravinder Abrol, Pasadena, CA (US);

William A. Goddard, Pasadena, CA (US);

Adam R. Griffith, Pasadena, CA (US);

Victor Wai Tak Kam, New York, NY (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G06F 19/00 (2018.01); G01N 33/68 (2006.01); C07K 14/705 (2006.01);
U.S. Cl.
CPC ...
C07K 14/705 (2013.01); G01N 2500/04 (2013.01);
Abstract

A method for practical prediction of the three-dimensional structure of α-helical membrane proteins (HMPs) is described. The method allows one to predict the binding site and structure for strongly bound ligands. The method combines a protocol of computational methods enabling a complete ensemble of packings to be sampled and systematically reducing this ensemble to progressively more accurate structures until at the end there remain a few that might be functionally relevant and likely to play a role in all binding and activation processes. This method is well suited to automatic operation making it practical to obtain, for example, the ensemble of important structures for all human GPCRs. With this ensemble of all active GPCR structures in the human body, an infimum method is presented to maximize efficacy toward the selected target while minimizing binding to all other GPCRs to eliminate toxicity arising from cross-reacting with other GPCRs (a most common source of drug failure). This infimum method is broadly applicable to any set of proteins where a ligand is desired to be able to modulate the function of one protein while not affecting the function of other proteins.


Find Patent Forward Citations

Loading…